

Zydus Lifesciences- first in India to launch protection against new strain of influenza virus (Southern Hemisphere 2025)

Quadrivalent Inactivated Influenza vaccine - VaxiFlu - 4 to offer seasonal protection against 4 new virus strains.

Ahmedabad, India 26th February, 2025

Zydus, a leading, discovery-based, global pharmaceutical company is ready to launch the season's first India's Flu protection as per WHO recommended composition of quadrivalent influenza virus vaccines for use in the 2025 southern hemisphere. The company's Quadrivalent Inactivated Influenza vaccine VaxiFlu-4 will offer protection against A/Victoria/4897/2022 (H1N1)pdm09-like virus, A/Croatia/10136RV/2023 (H3N2)-like virus, B/Austria/1359417/2021 (B/Victoria lineage)-like virus, B/Phuket/3073/2013 (B/Yamagata lineage)-like virus¹. A quadrivalent vaccine, by covering strains of both influenza A and influenza B, provides a broader protection and significantly reduces the risk of vaccine mismatch. The vaccine has been cleared by the Central Drug Laboratory (CDL).

VaxiFlu-4 is being marketed by Zydus Vaxicare-a division of the group focussing on preventives. The Quadrivalent Inactivated Influenza vaccine has been developed at the Vaccine Technology Centre (VTC) in Ahmedabad which has proven capabilities in researching, developing, and manufacturing of safe and efficacious vaccines.

Speaking on the development Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited said, "Preventives are the key to public health in both the developing and the developed world and vaccines have the potential to improve the quality of life. In India, there is a pressing need for access to affordable, high-quality vaccines that can address healthcare challenges. With vaccines like VaxiFlu-4 we are serving the cause of public health through annual immunisation and preventing flu outbreaks."

Because of annual and occasional outbreaks, the control of influenza has become a major public health challenge. Annual Influenza (flu) vaccination is the best way to prevent flu and its potentially serious complications. Influenza is a contagious respiratory illness caused by influenza viruses which spreads from person to person, mainly through airborne respiratory droplets generated from coughing and sneezing or direct contact with an infected surface or individual². It can cause illnesses that range in severity and at times lead to hospitalization and death-with the latter occurring mainly in high-risk groups, such as under-five children, the elderly, and people with immunosuppressive and chronic medical conditions². According to the World Health Organization (WHO), seasonal influenza results in 290,000-650,000 deaths every year³.



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878

About Zydus

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. The Vaccine Technology Centre has developed a wide spectrum of 17 vaccines including the Conjugated Typhoid Vaccine, MMR, MR, Hepatitis B and anti-rabies vaccines. Besides this, a few vaccines such as Hepatitis A vaccine, Hepatitis E vaccine, MMRV vaccine and Bivalent Typhoid and Paratyphoid A Conjugate vaccine which are undergoing clinical trials and several vaccines are in pre-clinical stage. For more details visit www.zyduslife.com

References:

1. Downloaded from [sep-2024-sh-recommendations_seasonal_final.pdf](#), Last Accessed on 08/02/2025 at 12:14 PM
2. Jayaram A, Jagadesh A, Kumar AMV, Davtyan H, Thekkur P, Vilas VJDR, Mandal SK, Sudandiradas R, Babu N, Varamballi P, Shetty U, Mukhopadhyay C. Trends in Influenza Infections in Three States of India from 2015-2021: Has There Been a Change during COVID-19 Pandemic? *Trop Med Infect Dis.* 2022 Jun 19;7(6):110. doi: 10.3390/tropicalmed7060110. PMID: 35736988; PMCID: PMC9228248.
3. World Health Organization Influenza (Seasonal) [https://www.who.int/news-room/fact-sheets/detail/influenza-\(seasonal\)](https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)) Last accessed on 08/02/2025 at 12:22 pm



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878